DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR HYDROXYUREA
Clinical Trials for Hydroxyurea
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00000586 | Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH) | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | To assess the efficacy and safety of orally administered hydroxyurea in the treatment of painful crises in patients with sickle cell anemia. |
| NCT00000602 | Pediatric Hydroxyurea in Sickle Cell Anemia (PED HUG) | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 | To determine whether hydroxyurea prevents the onset of chronic end organ damage in young children with sickle cell anemia. |
| NCT00000623 | Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN) | Completed | National Heart, Lung, and Blood Institute (NHLBI) | N/A | The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used. |
| NCT00000623 | Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN) | Completed | Thalassemia Clinical Research Network | N/A | The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used. |
| NCT00000623 | Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN) | Completed | New England Research Institutes | N/A | The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used. |
| NCT00000916 | A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | This study compares the safety and effectiveness of continuing your current anti-HIV medications to that of adding or switching some of your anti-HIV medications. It will follow the effect of these medication changes, including the addition of hydroxyurea (HU), on long-term viral suppression. Other medications which may be added include didanosine (ddI) and/or stavudine (d4T). Patients receiving combination antiretroviral therapy with indinavir (IDV), zidovudine (ZDV)(or d4T) and lamivudine (3TC) show viral suppression for two years or more. Discontinuation of one or two of these drugs results in prompt loss of the viral suppression. Other studies show that addition of HU to some reverse transcriptase inhibitor treatments results in increased antiviral effects. This study will provide further information on the effect of adding HU to a treatment regimen with respect to long-term viral suppression. |
| NCT00000919 | A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | N/A | The purpose of this study is to compare the effectiveness of various combinations of anti-HIV drugs in HIV-positive men and women. Patients receive specific combinations of 3 or 4 of the following 6 drugs: didanosine (ddI), stavudine (d4T) efavirenz (EFV), nelfinavir (NFV), lamivudine (3TC), or zidovudine (ZDV). Anti-HIV therapy is effective in preventing the spread of HIV in the body. However, patients often experience unpleasant side effects and have difficulties following the dosing schedule. This study looks for combinations of anti-HIV drugs ("cocktails") which will be the most effective with the fewest problems. |
| Trial ID | Title | Status | Sponsor | Phase | Summary |
Clinical Trial Conditions for Hydroxyurea
Condition Name
Clinical Trial Locations for Hydroxyurea
Trials by Country
Clinical Trial Progress for Hydroxyurea
Clinical Trial Phase
Clinical Trial Sponsors for Hydroxyurea
Sponsor Name
